CHRS
Coherus Oncology·NASDAQ
--
--(--)
--
--(--)
5.23 / 10
Netural
Capital flows show a 7.69/10 score, indicating robust liquidity despite a negative overall trend; small-cap inflows are positive, hinting at underlying demand. Analyst coverage is limited but unanimously bullish, adding a speculative tailwind.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-22
InstitutionOppenheimer
Times predicted1
Historical Win Rate100.0%
What is the market sentiment for CHRS?
- CHRS holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.23/10 (Netural).
